| Background: This project aimed to evaluate the serum survivin in SLE cases compared with healthy individuals and to investigate the serum survivin as a possible biomarker in predicting SLE clinical features.
Method: In a case-control research, 62 SLE patients based on the Systemic Lupus International Collaborating Clinics (SLICC) classification and 92 age- and sex-matched healthy individuals were enrolled. Complete history taking, detailed physical examination, and laboratory tests were done. Disease activity was evaluated via systemic lupus erythematosus disease activity index 2000 (SLEDAI-2K). Serum survivin was measured via ELISA.
Results: Serum survivin level in SLE cases was considerably lower than healthy individuals (P=0.05). Serum survivin in active SLE patients, inactive SLE patients and healthy individuals were 92.6 (41-130), 114.5 (41-632.5) and 120.4 (9-2992.5) pg/mL, respectively. Serum survivin was considerably lower in active SLE cases compared with healthy individuals (P=0.05). Although serum survivin levels in active SLE cases were lower than inactive SLE group, the difference did not receive significant level (P>0.05). Moreover, no significant association was noticed between demographic and clinical features of patients with serum survivin levels (P>0.05). There was no significant correlation between disease activity, organ involvement and negative or positivity of autoantibodies as well as serum complement with survivin levels (P>0.05).
Conclusion: Serum survivin in SLE patients especially patients with active disease is lower than healthy individuals. However, there is no significant association between serum survivin levels with demographic and clinical characteristics of SLE. |